Parabilis Medicines

Mathai Mammen, M.D., Ph.D. recently participated in a dynamic panel at the Longwood Healthcare Leaders #BostonCEO meeting, where he joined distinguished executives Alexandra (Sandra) Glucksmann, CEO of Sensorium Therapeutics, Theresa Heah, CEO of Paratus Sciences, Sekar (Sek) Kathiresan, CEO of Verve Therapeutics, expertly moderated by John Lepore, MD, CEO of ProFound Therapeutics.    The panelists explored non-scientific factors that influence success in biotech and pharma. Mathai highlighted the crucial role of an empowered, curious, and committed project team leader—the elusive "drug hunter.” In pursuing our goal of transformative medicines, we at Parabilis Medicines embrace the notion that culture and science are equally important in this creative journey and mission.     Thank you to the organizers at Longwood for assembling an excellent panel of CEOs and senior executives from across the biopharmaceutical ecosystem.  #LongwoodHealthcareLeaders #Biotech #TranslationalMedicine 

Did you know that the majority of natural proteins contain at least one alpha helix? These structures play critical roles in folding, protein and DNA binding, membrane anchoring, and other essential biological processes.       With our Helicon platform, we’ve leveraged the unique capabilities of alpha helices to create a novel class of therapeutics. These stabilized helical peptides are capable of efficient cell entry and modulation of protein-protein and protein-DNA interactions — opening up a vast realm of possibilities to reach targets inaccessible to other kinds of medicines.      Learn more about Helicons here: https://lnkd.in/eWzFMkt9      #Biotechnology #Helicons #CreatingExtraordinaryMedicines   

We’ve come quite far from where we began at FogPharma — from inventing the basics of the Helicon technology to now being in the clinic with our first medicine, with four late discovery programs behind it; an expanded platform that seamlessly integrates highly innovative AI and experimental technologies; and programs spanning functional inhibitors, degraders, and radiopharmaceuticals. It’s in celebration of this rich history and thrilling future that we’re excited to unveil the next chapter in our storied history, as ✨ Parabilis Medicines ✨.   The word Parabilis draws on Greek and Latin etymologies to mean both ‘beyond what’s possible’ and also ‘obtainable’ — a perfect encapsulation of our drive to expand what is therapeutically possible for the treatment of serious diseases, and our commitment to ensuring our medicines reach and benefit patients globally. Learn more about what this new name means to us in today’s press release about the news: https://bit.ly/3C0HHX7 And explore our new website, at www.parabilismed.com, to find all-new details about our platform, our pipeline, and the exciting story of how we got here and where we’re going.  #ParabilisMedicines #CreatingExtraordinaryMedicines #Biotechnology

We were honored to host Eric Schadt, a leading figure in computational biology and precision medicine, at our offices recently. In his current roles as CSO of Pathos, Dean for Precision Medicine at the Icahn School of Medicine at Mount Sinai, and across the rest of his distinguished career, Dr. Schadt has driven innovation in the use of data science to pair precise patient populations with more targeted interventions — something we’re passionately advancing here at FogPharma as well.  With over 500 peer-reviewed publications and an h-index of 146, Eric's insights were both groundbreaking and inspiring. Dr. Schadt spoke with our team about how causal AI — a type of AI that can make inferences using causal reasoning — can bolster the development of biomarker-driven cancer treatments. He also shared some of the cutting-edge precision medicine approaches he has been developing.  Thank you, Dr. Schadt, for sharing your time with us!   #Biotech #DataScience #ArtificialIntelligence #PrecisionMedicine 

#DYK: Mutations in the Wnt/β-catenin signaling pathway drive millions of cancer cases globally, including up to 90% of colorectal cancers. Despite this, there have been no approved therapies targeting this pathway.  Our lead candidate, FOG-001, is the first and only direct inhibitor of β-catenin interactions with the T-cell factor (TCF) family of transcription factors.     FOG-001 is in a Phase 1/2 clinical trial studying its safety and efficacy in patients with colorectal cancer and other solid tumors.      Our drug discovery pipeline includes multiple ambitious projects aimed at improving the lives of many more patients. Learn more here: https://lnkd.in/eW72MPzq    #Biotech #DrugDiscovery #Oncology #CancerResearch 

We’re excited to share that we have been named a 2024 BostInno Fire Award honoree!     As we expand our impact within the #BostonBiotech community, this honor reflects the hard work of our diverse and talented team, our commitment to advancing life-changing medicines, and our dedication to improving patient outcomes. We’re proud to be recognized among the incredible organizations driving progress in the local ecosystem and look forward to celebrating with the other honorees on November 18th.     #BostInno #Biotech #DrugDiscovery #Oncology 

Join us in welcoming Jack Russella Pollard to our leadership team as Vice President, Computational Biology. His deep knowledge of translational research and innovative approaches will be pivotal in advancing our mission to incorporate data science into drug discovery and development. Jack brings nearly 20 years of oncology Discovery and Early Development experience, having built and led interdisciplinary teams at HiFiBio, Moderna, and Sanofi. With expertise in data science, genomics, and AI-driven methods, Jack will spearhead efforts to integrate data-driven insights across our programs, guiding critical decisions from discovery through clinical development. #Biotech #Oncology #DataScience

Last weekend, our team participated in the Jimmy Fund Walk, joining thousands of others to support the fight against cancer.    Walking together reminded us of the broader mission we’re part of — not just creating groundbreaking therapies but supporting patients facing a cancer diagnosis and their loved ones.    Between our corporate donation and the fundraising of our team we were proud to contribute over $6,000 to the Jimmy Fund’s longstanding work on behalf of cancer research and treatment at the Dana-Farber Cancer Institute.   From marathoners to 5K walkers, it was inspiring to see our community come together for such a meaningful cause. If you’d like to contribute, it’s not too late to donate to the FogPharma Team - Boston Marathon Jimmy Fund Walk: https://bit.ly/3BI2U8f     #JimmyFundWalk 

The World Health Organization #WorldMentalHealthDay today focuses on the topic of mental health at work. We at FogPharma strongly believe in fostering a healthy workplace and a sense of purpose, belonging, growing, and thriving in our team.  We have high ambition to develop extraordinary medicines for patients.  Our “all-in” work requires stamina and sustainability. Today our team is dedicating time to learn strategies for self-care and preventing burnout and cultivating a caring team culture and skills for supporting one another. Because supporting our employees’ mental health is essential to creating an environment where our teams – and our pursuit of innovation – can thrive. Learn more here: https://bit.ly/3BGwknd   #MentalHealthMatters #Biotech 

As we continue to advance FOG-001 through the clinic, we’re deepening our team of drug development experts. We’re excited to announce that Nicolas Mourier, PhD recently joined us as Vice President, Pharmaceutical Development. He’ll provide technical and operational leadership for our drug development activities and guide the strategic direction of our development-stage pipeline.     Nicolas brings more than 25 years of global experience in pharmaceutical development, and has a track record of implementing successful CMC strategies across a wide range of therapeutic areas. His expertise in guiding drugs from preclinical to commercial stages will be an asset as we progress our pipeline of Helicon peptide therapies.    Welcome to the team, Nicolas!    #Biotech #DrugDevelopment #Oncology